Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 6, 1996

View Archived Issues

New analgesic compounds with novel mechanism of action disclosed by Novo Nordisk

Anti-E-selectin antisense compound from Isis inhibits mRNA splicing

ChemGenics/Wyeth-Ayerst antibacterial drug discovery collaboration

Cytovene approved for new indication in U.S.

Connective Therapeutics acquires rheumatoid arthritis Rx from SKB

PAI-1 diagnostic approved for marketing in U.S.

Successful pivotal Mexican trial for oral impotency therapy

Varian, University of Arizona collaborate on methods of enhancing gene therapy efficacy

FDA tentatively approves generic NSAID

SKB, IDEC initiate phase III testing of antirheumatic antibody

Oncogene Science issued patent on gene transcription

Cytel to implement new development strategy for HBV vaccine

Etex signs marketing agreement for bone substitute

Sepracor gets go-ahead for U.S. clinical trials on (S)-oxybutynin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 24, 2025.
Moderna expands mRNA tech to latent viruses, cancer, rare disease
BioWorld
Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
Otsuka licenses Harbour’s bispecific T-cell engager for $670M
BioWorld
Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd....
Revmed goes global with $2B in capital for RAS(ON) inhibitors
BioWorld
Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to...